COLL Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Collegium Pharmaceutical Inc. (COLL) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and growth potential in its pain portfolio and Jornay product make it an attractive option despite neutral technical indicators and lack of recent news catalysts.
The MACD is below zero and negatively expanding, indicating bearish momentum. RSI is neutral at 37.511, and moving averages are converging, showing no clear trend. The stock is trading near support levels (S1: 44.624), with resistance at 46.657. Overall, the technical indicators suggest a neutral to slightly bearish trend.
Strong financial performance in Q3 2025, with revenue up 31.42% YoY, net income up 237.51% YoY, and EPS up 211.11% YoY.
Positive analyst sentiment with multiple Buy ratings and price target increases, highlighting growth potential in Jornay and the pain portfolio.
Upcoming earnings report on 2026-02-26, which could provide further positive momentum.
Lack of significant trading trends from hedge funds and insiders.
No recent news or event-driven catalysts.
Neutral technical indicators and slightly bearish MACD.
In Q3 2025, Collegium Pharmaceutical reported strong financial growth: Revenue increased by 31.42% YoY to $209.36M, net income surged by 237.51% YoY to $31.51M, EPS grew by 211.11% YoY to $0.84, and gross margin improved to 61.7%, up 1.55% YoY.
Analyst sentiment is positive, with multiple Buy ratings and price target increases. Recent updates include Truist raising the price target to $58, H.C. Wainwright increasing it to $60, and Barclays maintaining an Overweight rating with a $56 target. Analysts highlight the durability of the pain portfolio, growth potential of Jornay, and multi-year growth runway.
